Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04930991 · ClinicalTrials.gov registry record · Early Phase 1
High Dose Omeprazole in Patients With Pancreatic Cancer
A Early Phase 1 study of Exocrine Pancreatic Cancer, sponsored by University of Oklahoma.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT04930991 is a Early Phase 1 study of Exocrine Pancreatic Cancer that is actively recruiting participants, run by University of Oklahoma. The registered enrollment target is 60 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04930991, a Early Phase 1 study of Exocrine Pancreatic Cancer, is actively recruiting participants, sponsored by University of Oklahoma.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test the safety of high dose omeprazole and see what effects that it has on patients with exocrine pancreatic cancer.
Conditions Studied
Interventions
- DRUG Omeprazole
Study Locations (1)
Oklahoma
- Stephenson Cancer Center - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2021-09-07 |
| Est. Completion | 2027-09 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04930991
The ClinicalTrials.gov registry entry for NCT04930991 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Exocrine Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Omeprazole is the first listed.
NCT04930991 reports 1 study location spanning 1 distinct geographic area - top geographies include Oklahoma.
Frequently Asked Questions
What is clinical trial NCT04930991 about?
NCT04930991 is a clinical study titled "High Dose Omeprazole in Patients With Pancreatic Cancer". The purpose of this study is to test the safety of high dose omeprazole and see what effects that it has on patients with exocrine pancreatic cancer.
What is the current status of trial NCT04930991?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 60 participants. The study started on 2021-09-07. Estimated completion is 2027-09.
What conditions does trial NCT04930991 study?
This clinical trial studies the following conditions: Exocrine Pancreatic Cancer.
What interventions are being tested in trial NCT04930991?
The interventions under investigation include: Omeprazole (DRUG).
Who is sponsoring clinical trial NCT04930991?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04930991 being conducted?
This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Exocrine Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.